tiprankstipranks
Viracta Therapeutics Highlights Strategic Focus and Financials
PremiumCompany AnnouncementsViracta Therapeutics Highlights Strategic Focus and Financials
1M ago
Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year
Premium
The Fly
Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year
1M ago
Viracta Therapeutics expects cash to fund operations into Q1 of 2025
Premium
The Fly
Viracta Therapeutics expects cash to fund operations into Q1 of 2025
1M ago
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
PremiumThe FlyViracta Therapeutics price target lowered to $4 from $6 at RBC Capital
4M ago
Viracta Therapeutics Announces Key Business Developments
Premium
Company Announcements
Viracta Therapeutics Announces Key Business Developments
5M ago
Viracta Therapeutics announces data from Phase 2 NAVAL-1 trial
Premium
The Fly
Viracta Therapeutics announces data from Phase 2 NAVAL-1 trial
5M ago
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
PremiumThe FlyViracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
7M ago
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
Premium
Company Announcements
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
8M ago
Viracta Therapeutics appoints Faerm as Chief Financial Officer
Premium
The Fly
Viracta Therapeutics appoints Faerm as Chief Financial Officer
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100